Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Julio RosenstockChristopher H SorliMichael E TrautmannCristóbal MoralesUlrich WendischGeorge DaileyMarcus HompeschIn Young ChoiJahoon KangJohn StewartKun-Ho YoonPublished in: Diabetes care (2019)
Efpeglenatide once weekly led to significant reductions in HbA1c and weight, with a safety profile consistent with the GLP-1 RA class in patients with early T2D mostly on metformin monotherapy.
Keyphrases
- ankylosing spondylitis
- body weight
- glycemic control
- type diabetes
- disease activity
- rheumatoid arthritis
- blood glucose
- weight loss
- insulin resistance
- hiv infected
- systemic lupus erythematosus
- combination therapy
- open label
- physical activity
- body mass index
- randomized controlled trial
- adverse drug
- systemic sclerosis
- weight gain
- antiretroviral therapy
- study protocol